2-Bromo-N-(2-hydroxymethyl-adamantan-2-yl)-acetamide | 180258-68-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Bromo-N-(2-hydroxymethyl-adamantan-2-yl)-acetamide
• 英文别名: 2-bromo-N-[2-(hydroxymethyl)-2-adamantyl]acetamide
• CAS: 180258-68-8
• 化学式: C₁₃H₂₀BrNO₂
• 分子量: 302.211
• InChiKey: OSNDUSNPUMDVQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Bromo-N-(2-hydroxymethyl-adamantan-2-yl)-acetamide 在 氢氧化钾 、 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 为溶剂， 反应 52.0h， 生成 4-(ethoxycarbonyl)spiro[morpholine-3,2'-tricyclo[3.3.1.1^3,7]decane]
  参考文献：
  名称：

  Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2

  摘要：

  The synthesis of some new aminoadamantane derivatives is described. The new compounds were evaluated against a wide range of viruses [influenza A H1N1, influenza A H2N2, influenza A H3N2, influenza B, parainfluenza 3, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient (TK-) HSV-1, vaccinia, vesicular stomatitis, polio 1, Coxsackie B4, Sindbis, Semliki forest, Reo 1, varicella-zoster virus (VZV), TK- VZV, human cytomegalo-virus (HCMV),,and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)]. Some of them proved markedly active against the influenza A H2N2 (compounds 4a,b, 5a, 6a, and 7a), H3N2 (compounds 5a, 6a, and 7a), and H1N1 (compounds 4b,c and 6d). Since compounds 5a, 6a, and 7a, amantadine, and rimantadine showed the same comparative pattern of potency against influenza strains H2N2, H3N2, and B, it may postulated that they act according to a similar mechanism, with regard to their ''amine'' effect, on the M2 ion channel of influenza A (H1N1, H2N2, or H3N2). In general, no significant activity was noted with any of the new compounds against any of the other viruses tested, making their activity against influenza virus more specific and striking. Borderline activity was noted with some of the compounds (4b,c, 5a-c, and 8a) against HIV-1.

  DOI：

  10.1021/jm950891z
• 作为产物：
  描述：

  2-nitro-2-adamantanemethanol 在 镍 氢氧化钾 、 氢气 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 50.0 ℃ 、6.0 kPa 条件下， 反应 7.0h， 生成 2-Bromo-N-(2-hydroxymethyl-adamantan-2-yl)-acetamide
  参考文献：
  名称：

  Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2

  摘要：

  The synthesis of some new aminoadamantane derivatives is described. The new compounds were evaluated against a wide range of viruses [influenza A H1N1, influenza A H2N2, influenza A H3N2, influenza B, parainfluenza 3, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient (TK-) HSV-1, vaccinia, vesicular stomatitis, polio 1, Coxsackie B4, Sindbis, Semliki forest, Reo 1, varicella-zoster virus (VZV), TK- VZV, human cytomegalo-virus (HCMV),,and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)]. Some of them proved markedly active against the influenza A H2N2 (compounds 4a,b, 5a, 6a, and 7a), H3N2 (compounds 5a, 6a, and 7a), and H1N1 (compounds 4b,c and 6d). Since compounds 5a, 6a, and 7a, amantadine, and rimantadine showed the same comparative pattern of potency against influenza strains H2N2, H3N2, and B, it may postulated that they act according to a similar mechanism, with regard to their ''amine'' effect, on the M2 ion channel of influenza A (H1N1, H2N2, or H3N2). In general, no significant activity was noted with any of the new compounds against any of the other viruses tested, making their activity against influenza virus more specific and striking. Borderline activity was noted with some of the compounds (4b,c, 5a-c, and 8a) against HIV-1.

  DOI：

  10.1021/jm950891z

文献信息

• Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2
  作者：Nicolas Kolocouris、Antonios Kolocouris、George B. Foscolos、George Fytas、Johan Neyts、Elisabeth Padalko、Jan Balzarini、Robert Snoeck、Graciela Andrei、Erik De Clercq

  DOI：10.1021/jm950891z

  日期：1996.1.1

  The synthesis of some new aminoadamantane derivatives is described. The new compounds were evaluated against a wide range of viruses [influenza A H1N1, influenza A H2N2, influenza A H3N2, influenza B, parainfluenza 3, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient (TK-) HSV-1, vaccinia, vesicular stomatitis, polio 1, Coxsackie B4, Sindbis, Semliki forest, Reo 1, varicella-zoster virus (VZV), TK- VZV, human cytomegalo-virus (HCMV),,and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)]. Some of them proved markedly active against the influenza A H2N2 (compounds 4a,b, 5a, 6a, and 7a), H3N2 (compounds 5a, 6a, and 7a), and H1N1 (compounds 4b,c and 6d). Since compounds 5a, 6a, and 7a, amantadine, and rimantadine showed the same comparative pattern of potency against influenza strains H2N2, H3N2, and B, it may postulated that they act according to a similar mechanism, with regard to their ''amine'' effect, on the M2 ion channel of influenza A (H1N1, H2N2, or H3N2). In general, no significant activity was noted with any of the new compounds against any of the other viruses tested, making their activity against influenza virus more specific and striking. Borderline activity was noted with some of the compounds (4b,c, 5a-c, and 8a) against HIV-1.